Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 1278

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 8
Chunk 1278
---
 until present, Mr. Schafer
has been serving as the Chief Commercial Officer, and EVP Business Development at Zevra Therapeutics, a rare disease company. From November
2022 until January 2023, Mr. Schafer was interim Chief Executive Officer and Chair of the
board of directors at PHARNEXT, an entity he has served on the board of directors since July 2020. From December 2020 until November
2022, Mr. Schafer served as Senior Vice President and General Manager, Autoimmune and Rare Disease Business for Mallinckrodt Pharmaceuticals
Incorporated. In addition, he served as Chief Strategy and Business Development Officer from September 2019 until December 2020, and
from 2015 to September 2019 he was SCP of Business Development and General Manager of International Operations at Mallinckrodt Pharmaceuticals.
From 2009 until 2015, he served as Vice President and Oncology Therapeutic Area Head at Astellas Pharmaceuticals Incorporated, where
he was responsible for building the company’s global oncology franchise. From 2000 until 2009, Mr. Schafer served in positions
of increasing seniority at Takeda Pharmaceuticals North America, including Manager and Senior Manager, New Product and New Business Development;
Senior Product Manager, Gastrointestinal Marketing; and Director, Oncology and Renal Marketing and Commercial Development. He began working
in the healthcare and pharmaceutical industry in 1998 and has served in various positions including management consulting at Accenture
(formerly Anderson Consulting), G.D. Searle & Co. (later acquired by Pfizer) and Cognia Corporation. He received his Bachelor of
Arts in Biology and German at the University of Notre Dame, his MS in Biotechnology from Northwestern University and his MBA from Northwestern
University. We believe Mr. Schafer’s extensive experience in pharmaceutical strategy, marketing and business development will assist
our Board of Directors’ oversight role as we build and develop our Company.

Chris
H. Senanayake, Ph.D. Dr. Senanayake was appointed to be a member of the Company’s Board of Directors in 2021. In 2019, Dr.
Senanayake founded TCG GreenChem, Inc., a U.S. subsidiary of TCG Lifesciences Pvt. Ltd., a leading global Contract Research and Manufacturing
Services (CRAMS) company in the area of drug discovery, development and commercialization, where he serves as chief executive officer